Recent decades have witnessed a significant increase in the incidence of diabetes mellitus primarily driven by population trends toward weight gain and sedentary lifestyles. Diabetes mellitus is a leading cause of blindness, renal failure, lower limb amputation, and an independent risk factor for atherosclerotic cardiovascular disease (CVD) and stroke. In fact, individuals with diabetes have a two-to fourfold increased risk of myocardial infarction (MI) and stroke that accounts for over 65% of diabetic mortality. Despite a vast amount of research, the molecular and cellular mechanisms that predispose individuals with diabetes to the development and progression of atherosclerosis are not understood. This chapter summarizes the current state of our knowledge of these conditions as well as some of the animal models that are being used to further increase our understanding. In addition, pathways and mechanisms that may link diabetes, and hyperglycemia in particular, to the development and progression of atherosclerosis are discussed. The continued investigation of identified pathways, linking hyperglycemia and diabetes mellitus to atherosclerosis, and the discovery of novel mechanisms and targets will be important to the development of new and effective antiatherosclerotic therapies tailored to individuals with diabetes.
Introduction
The last few decades have witnessed a dramatic, worldwide increase in the incidence of diabetes mellitus. Driven by changes in lifestyle and an escalating rate of obesity, the number of individuals with diabetes is expected to reach 300 million by the year 2025 [1, 2] . Therefore, the diabetes epidemic is, and will continue to be, a global health crisis. Complications associated with diabetes make it a leading cause of blindness, renal failure, and lower limb amputations as well as an important, independent risk factor for atherosclerotic cardiovascular disease (CVD). CVD accounts for over 65% of diabetic mortality. In fact, diabetes mellitus is "a coronary heart disease risk equivalent" meaning that individuals with diabetes have the same risk of myocardial infarction (MI) as nondiabetic persons who have had a previous MI [3] [4] [5] . Despite a tremendous amount of research, the treatment and prevention of diabetes-associated CVD is currently limited by our lack of understanding of the molecular and cellular mechanisms by which diabetes mellitus promotes atherosclerosis. This chapter will focus upon our current understanding of this problem, the model systems that are being used to further increase our knowledge and the potential future directions of this research.
Diabetes Mellitus
Diabetes mellitus is currently defined as a condition with casual blood glucose values are ≥11.1 mmol/L, or fasting plasma glucose ≥7.0 mmol/L, or glucose levels ≥11.1 mmol/L 2 h after an oral glucose tolerance test [6] . Pathologically, the term diabetes mellitus describes a heterogeneous group of metabolic disorders characterized by chronic hyperglycemia. These include conditions under which the body cannot produce insulin and/or cannot effectively respond to the insulin that is being produced. There are two major forms of diabetes; type 1 (T1D), formerly known as juvenile diabetes or insulin-dependent diabetes mellitus (IDDM) and type 2 (T2D), formerly known as adult onset or noninsulin-dependent diabetes mellitus (NIDDM). T1D and T2D are, in essence, two distinctly different diseases that present an overlapping array of signs and symptoms.
T1D is characterized by an absolute insulin deficiency that results from an autoimmune-mediated depletion of insulin secreting pancreatic β cells [7, 8] . Typically, T1D develops with a rapid onset in children, with a peak incidence at 14 years of age. T1D makes up approximately 10% of the total number of cases of diabetes mellitus. Recent breakthroughs in β cell transplantation may lead to an eventual cure for T1D. Until that time, the only treatment is the tight self-monitoring of plasma glucose and the administration of exogenous insulin according to carbohydrate intake.
T2D accounts for the remaining 90% of cases of diabetes mellitus. T2D is characterized by a relative insulin deficiency that arises from a combination of peripheral tissue insulin resistance and impaired β cell function [9, 10] . Tissues expressing the insulin responsive GLUT4 glucose transporter, including adipose, and skeletal muscle and liver are particularly relevant to insulin resistance. The onset of T2D is relatively gradual and, until recently, with rare exceptions, affected only adults. However with the dramatic increase in childhood obesity, there has been an alarming increase in the diagnosis of T2D in children. Depending on severity, T2D can be controlled by using a combination of lifestyle modifications (diet and exercise), medications that increase insulin sensitivity and exogenous insulin.
Despite their distinctly different etiologies, both T1D and T2D are characterized by chronic hyperglycemia. Furthermore, there is a strong correlation between hyperglycemia and both micro-and macrovascular disease [11] [12] [13] [14] [15] .
